The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 543-547

  Vredenburgh, J ^a   Fishman, R ^a   Coniglio, D ^a   Matters, L ^a   Elkordy, M ^a   Ross, M ^a   Hussein, A ^a   Rubin, P ^a   Gilbert, C ^a   Petros, W ^a   Peters, W P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast carcinoma; Continuous infusion 5 fluorouracil; Paclitaxel

Indexed keywords

CARBOPLATIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN TOXICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; REMISSION INDUCTION;

EID: 0031768083     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00003     Document Type: Article

References (33)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;46:1-16.
2. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
3. Budd GT, Green S, O'Bryan RM, et al. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol 1995;13:831-9.
4. Ung O, Langlands AO, Barraclough B, Boyages J. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol 1995;13:435-43.
5. Greenberg AC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
6. Ahern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-5.
7. Ravdin PM. Taxoids: effective agents in anthracycline-resistant breast cancer [review]. Semin Oncol 1995;22(suppl 13):29-34.
8. Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-51.
9. Smith GA. Current status of vinorelbine for breast cancer [review]. Oncology 1995;9:767-73.
10. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
11. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
12. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
13. Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the U.S. experience. Semin Oncol 1996;23(suppl 1):48-52.
14. Klaassen U, Harstrick A, Wilke H, Seeber S. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. Semin Oncol 1996;23(suppl 1):44-7.
15. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ. 5-Fluorouracil plus leucovorin in women with metstatic breast cancer: a phase II study. Am J Clin Oncol 1991;14:30-2.
16. Fine S, Erlichman C, Kaizer L, Warr D, Gadalla T. Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Res Treat 1994;30:205-9.
17. Zaniboni A, Meriggi F, Arcangeli G, Marpicati P, Montini E, Simoncini E, Marini G. L-folinic acid and 5-fluorouracil in the treatment of advanced breast cancer: a phase II study. Ann Oncol 1993;4(suppl 2):41-3.
18. Hansen R, Quebbeman E, Beatty P, et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 1987;10:145-9.
19. Anderson N. Infusional antimetabolites: an analytic review. Journal of Infusional Therapy 1991;1:4-16.
20. Lokich J, Ahigren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 1989;7:425-32.
21. Fraille RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223-8.
22. Sullivan RD, Young CW, Miller E, Glatstein N, Clarkson B, Burchenal JH. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxyuridine). Cancer Treat Res 1960;8:77-83.
23. Lokich JJ, Moore C. Chemotherapy associated palmar-plantar erythro-dysesthesia syndrome. Ann Int Med 1984;101:798-800.
24. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
25. Margolin KA, Green S, Osborne K, et al. Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer. Am J Clin Oncol 1994;17:175-80.
26. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-75.
27. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello II. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990;50:4199-203.
28. Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development [review]. Oncology 1995;9:1191-9.
29. Holmes FA, Watters RS, Theriault RL, et al. Phase II trial of taxol. an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
30. Holmes FA, Valero V, Theriault RL, Watters RS, Booser DS, Frye D, Hortobagyi GN. Phase II trial of taxol in metastatic breast cancer refractory to multiple prior treatments [abstract 178]. Proceedings of the American Society of Clinical Oncology 1993;12:60.
31. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
32. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
33. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 1994;21(suppl 8):29-33.